Despite being very effective and widely used, radiation oncology treatment still suffers from a lack of collective knowledge on how some treatments affects patients’ functioning, symptoms and quality of life, and how best to optimise their effectiveness. Such information is available through the outcome of clinical trials, but formal data-sharing is rather haphazard, particularly where new treatments are involved. With the advent of personalised cancer medicine, this means that patients may not always receive the most effective treatment in their particular case.
In a bid to put this situation to rights, the European Organisation for the Research and Treatment of Cancer (EORTC) and the European Society for Radiotherapy and Oncology (ESTRO) have joined forces to launch a new initiative, E2-RADIatE (EORTC-ESTRO Radiation Infrastructure for Europe). The initiative aims to put in place a pan-European infrastructure for a more efficient framework across the field of radiation oncology by encouraging collaboration that will also involve other oncology disciplines, in order to generate robust data on its role in cancer treatment and to further develop and integrate the discipline into therapeutic strategies.
OligoCare is the first project hosted on the E2-RADIatE platform that will collect data on the treatment of oligometastatic disease in lung, breast, prostate and colorectal cancer. There are 29 centres in 5 countries activated for E²-RADIatE, to start recruiting patients for OligoCare. It is anticipated that more centres and countries will follow in the coming years.
“Understanding what is happening in the real world will provide tremendous insights on best treatment for better care,” says Professor Damien Weber, Chair of the EORTC Radiation Oncology Group.